<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Agilent Technologies Inc — News on 6ix</title>
<link>https://6ix.com/company/agilent-technologies-inc</link>
<description>Latest news and press releases for Agilent Technologies Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/agilent-technologies-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68353e61741d205b31a20d0b.webp</url>
<title>Agilent Technologies Inc</title>
<link>https://6ix.com/company/agilent-technologies-inc</link>
</image>
<item>
<title>Agilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-to-announce-second-quarter-fiscal-year-2026-financial-results-on-may-27</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-to-announce-second-quarter-fiscal-year-2026-financial-results-on-may-27</guid>
<pubDate>Tue, 28 Apr 2026 20:15:00 GMT</pubDate>
<description>SANTA CLARA, Calif., April 28, 2026--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2026 after the stock market closes on Wednesday, May 27. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day.</description>
</item>
<item>
<title>Axion BioSystems and Agilent Technologies Resolve Litigation</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/axion-biosystems-and-agilent-technologies-resolve-litigation</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/axion-biosystems-and-agilent-technologies-resolve-litigation</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>ATLANTA, April 21, 2026--Axion BioSystems, Inc., a leading provider of live-cell analysis technologies, today announced that Agilent Technologies, Inc. and Axion BioSystems have fully resolved the issues in the two lawsuits between them, pending in the United States District Court for the District of Delaware, pursuant to the terms of a confidential settlement agreement.</description>
</item>
<item>
<title>Agilent Showcases Cancer Research Solutions at AACR 2026</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-showcases-cancer-research-solutions-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-showcases-cancer-research-solutions-at-aacr-2026</guid>
<pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., April 15, 2026--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for</description>
</item>
<item>
<title>Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-announces-the-biotek-cytation-9-cell-imaging-multimode-reader</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-announces-the-biotek-cytation-9-cell-imaging-multimode-reader</guid>
<pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., April 01, 2026--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform.</description>
</item>
<item>
<title>Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-receives-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-esophageal-or-gastroesophageal-junction-gej-carcinoma</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-receives-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-esophageal-or-gastroesophageal-junction-gej-carcinoma</guid>
<pubDate>Thu, 26 Mar 2026 12:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., March 26, 2026--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.</description>
</item>
<item>
<title>Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-showcases-advances-in-precision-oncology-and-digital-pathology-at-uscap-2026</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-showcases-advances-in-precision-oncology-and-digital-pathology-at-uscap-2026</guid>
<pubDate>Thu, 19 Mar 2026 12:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., March 19, 2026--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundati</description>
</item>
<item>
<title>Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-launches-agilent-advanced-therapeutics-unifying-cdmo-capabilities-across-canada-and-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-launches-agilent-advanced-therapeutics-unifying-cdmo-capabilities-across-canada-and-united-states</guid>
<pubDate>Wed, 11 Mar 2026 12:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., March 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States.</description>
</item>
<item>
<title>Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-to-acquire-biocare-medical-a-global-leader-in-clinical-and-research-pathology-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-to-acquire-biocare-medical-a-global-leader-in-clinical-and-research-pathology-solutions</guid>
<pubDate>Mon, 09 Mar 2026 07:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif. & SAN FRANCISCO, Calif., March 09, 2026--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million.</description>
</item>
<item>
<title>Agilent Reports First-Quarter Fiscal Year 2026 Financial Results</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-reports-first-quarter-fiscal-year-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-reports-first-quarter-fiscal-year-2026-financial-results</guid>
<pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
<description>SANTA CLARA, Calif., February 25, 2026--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025.</description>
</item>
<item>
<title>Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-to-participate-in-td-cowens-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-to-participate-in-td-cowens-46th-annual-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 21:15:00 GMT</pubDate>
<description>SANTA CLARA, Calif., February 23, 2026--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website.</description>
</item>
<item>
<title>Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-receives-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-eoc</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-receives-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-eoc</guid>
<pubDate>Thu, 12 Feb 2026 01:22:00 GMT</pubDate>
<description>SANTA CLARA, Calif., February 12, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.</description>
</item>
<item>
<title>Agilent Announces Cash Dividend of 25.5 Cents per Share</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-announces-cash-dividend-25-211500027</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-announces-cash-dividend-25-211500027</guid>
<pubDate>Wed, 11 Feb 2026 21:15:00 GMT</pubDate>
<description>SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026.</description>
</item>
<item>
<title>Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-presents-boehringer-ingelheim-with-inaugural-2025-instrument-tradein-impact-award</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-presents-boehringer-ingelheim-with-inaugural-2025-instrument-tradein-impact-award</guid>
<pubDate>Wed, 11 Feb 2026 13:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program.</description>
</item>
<item>
<title>Agilent Showcases Next‑Generation Automated Solutions at SLAS2026</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-showcases-nextgeneration-automated-solutions-at-slas2026</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-showcases-nextgeneration-automated-solutions-at-slas2026</guid>
<pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., February 04, 2026--Agilent Technologies Inc. (NYSE: A) announced today that it will present a range of next‑generation automated workflow innovations at the SLAS2026 International Conference & Exhibition, taking place February 7–11 in Boston, Massachusetts. Agilent will demonstrate how its expanding automation ecosystem—integrating advanced imaging, software, robotics, and AI‑powered optimization—supports laboratories in accelerating discovery with confidence, efficiency, an</description>
</item>
<item>
<title>Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-announce-first-quarter-fiscal-211500323</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-announce-first-quarter-fiscal-211500323</guid>
<pubDate>Mon, 02 Feb 2026 21:15:00 GMT</pubDate>
<description>SANTA CLARA, Calif., February 02, 2026--Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day.</description>
</item>
<item>
<title>Agilent Accelerates Digital Pathology with the Launch of the Agilent S540MD Slide Scanner System</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-accelerates-digital-pathology-with-the-launch-of-the-agilent-s540md-slide-scanner-system</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-accelerates-digital-pathology-with-the-launch-of-the-agilent-s540md-slide-scanner-system</guid>
<pubDate>Fri, 23 Jan 2026 13:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., January 23, 2026--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, available for sale in key European markets. The launch reflects Agilent’s continued investment in digital pathology, expanding its portfolio to meet the growing demand for high-throughput solutions in clinical laboratories.</description>
</item>
<item>
<title>Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/wasatch-biolabs-announces-co-marketing-agreement-with-agilent-to-advance-native-read-targeted-sequencing</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/wasatch-biolabs-announces-co-marketing-agreement-with-agilent-to-advance-native-read-targeted-sequencing</guid>
<pubDate>Fri, 19 Dec 2025 18:07:00 GMT</pubDate>
<description>Wasatch BioLabs (WBL), a leader in native, long-read sequencing and epigenomic analysis, today announced a co-marketing agreement with Agilent Technologies to support the adoption of its Direct Targeted Methylation Sequencing (dTMS) platform. The collaboration brings together Agilent's enrichment chemistries—SureSelect for genomic DNA and Avida for cell-free DNA—and WBL's proprietary Oxford Nanopore-based native-read workflow, expanding access to scalable targeted multi-omic analysis for RUO and</description>
</item>
<item>
<title>Agilent to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Tue, 16 Dec 2025 13:31:00 GMT</pubDate>
<description>SANTA CLARA, Calif., December 16, 2025--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference at 9 to 9:40 a.m. PST on Tuesday, Jan. 13, 2026.</description>
</item>
<item>
<title>Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-and-monash-university-malaysia-mark-15-year-partnership-with-new-biodiscovery-hub-to-drive-regional-biotech-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-and-monash-university-malaysia-mark-15-year-partnership-with-new-biodiscovery-hub-to-drive-regional-biotech-innovation</guid>
<pubDate>Fri, 05 Dec 2025 01:30:00 GMT</pubDate>
<description>Agilent Technologies Inc. (NYSE: A) announced the expansion of their strategic collaboration with Monash University in Malaysia to establish a state-of-the-art MUMPMP-Agilent BioDiscovery Hub aimed at accelerating regional biotechnology research and innovation. The new Memorandum of Understanding (MOU) was signed as part of the celebration of their 15-year strategic partnership, underscoring Agilent's continued commitment to advancing high-impact R&D capabilities in fast-growing Asian markets.</description>
</item>
<item>
<title>Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight</title>
<link>https://6ix.com/company/agilent-technologies-inc/news/agilent-announces-21-cfr-part-11-compliance-software-for-xcelligence-rtca-esight</link>
<guid isPermaLink="true">https://6ix.com/company/agilent-technologies-inc/news/agilent-announces-21-cfr-part-11-compliance-software-for-xcelligence-rtca-esight</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>SANTA CLARA, Calif., December 01, 2025--Agilent Technologies Inc (NYSE: A) today announced the release of a new 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RTCA) eSight system. The software includes a compliance license and enhanced security features, allowing this multiplex live-cell analysis system to be deployed not only in drug discovery and development labs but now also in GMP-regulated manufacturing and quality control settings. Extending the pla</description>
</item>
</channel>
</rss>